OmniSpirant Therapeutics is pioneering a novel approach to treat respiratory diseases and cancer through its innovative platform technology known as OmniSomes. This technology utilizes bioengineered stem cell exosomes, which are extracellular vesicles capable of delivering RNA and protein-based therapeutic cargoes directly to target cells in the lungs. The OmniSomes are designed to overcome significant barriers in pulmonary gene therapy, such as efficient aerosol delivery and penetration through the viscous mucus in the lungs. Collaborating with Aerogen Limited, OmniSpirant has optimized the formulation of OmniSomes to ensure high delivery efficiency while preserving the structural integrity of the exosomes. The platform has demonstrated promising results in preclinical studies, showing effective gene transfer in human lung cell models and small animal studies.

The therapeutic potential of OmniSomes extends beyond mere delivery; they are derived from stem cells, which are known for their regenerative properties. This technology not only aims to facilitate gene transfer but also harnesses the anti-inflammatory, anti-fibrotic, and tissue regeneration effects of stem cells to improve lung function in patients with chronic respiratory diseases. The company is initially focusing on developing first-in-class regenerative gene therapies for conditions such as cystic fibrosis and lung cancer, with plans to explore other diseases that may benefit from this advanced delivery system. The ethical sourcing of stem cells from healthy donors further underscores the commitment to safety and efficacy in their therapeutic development.

Ireland

Omnispirant is a biotechnology company that develops a novel platform technology using inhaled stem cell exosomes for treating respiratory diseases.

OmniSpirant Therapeutics

Company Details